AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for O-phosphoseryl-tRNA(Sec) selenium transferase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9HD40

UPID:

SPCS_HUMAN

Alternative names:

Liver-pancreas antigen; SLA-p35; SLA/LP autoantigen; Selenocysteine synthase; Selenocysteinyl-tRNA(Sec) synthase; Sep-tRNA:Sec-tRNA synthase; Soluble liver antigen; UGA suppressor tRNA-associated protein; tRNA(Ser/Sec)-associated antigenic protein

Alternative UPACC:

Q9HD40; A8K8W1; Q0D2P3; Q17RT1; Q9NXZ5; Q9UGM9; Q9Y353

Background:

O-phosphoseryl-tRNA(Sec) selenium transferase, known by alternative names such as Selenocysteine synthase and Soluble liver antigen, plays a pivotal role in selenoprotein biosynthesis. This enzyme is essential for converting O-phosphoseryl-tRNA(Sec) to selenocysteinyl-tRNA(Sec), a critical step in the synthesis of selenoproteins, which are vital for various cellular processes.

Therapeutic significance:

The enzyme's dysfunction is linked to Pontocerebellar hypoplasia 2D, a severe neurological disorder characterized by progressive brain atrophy, intellectual disability, and seizures. Understanding the role of O-phosphoseryl-tRNA(Sec) selenium transferase could open doors to potential therapeutic strategies for this debilitating condition.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.